Facial onset sensory and motor neuronopathy represents an exceptionally rare, debilitating neurodegenerative condition that challenges clinicians across neurological subspecialties. Recent advancements in structural and functional MRI have finally delineated distinct FOSMN neuroimaging markers in living patients. Although clinicians traditionally recognized the disorder as an isolated cranial neuropathy spreading rostro-caudally, cutting-edge volumetric analysis and diffusion tensor imaging confirm broader central nervous system involvement. Consequently, these findings provide crucial neuroanatomical insights into the systemic disease process that drives sensory and bulbar motor loss.

Clinical Phenotype and Diagnostic Challenges

Clinicians first identified facial onset sensory and motor neuronopathy in the early 2000s as an insidious neurological disorder. Typically, symptoms begin with persistent numbness or paresthesia across the trigeminal nerve distribution. Over several years, sensory disturbances advance caudally into the scalp, neck, trunk, and upper extremities. Furthermore, motor symptoms soon follow this sensory phase, causing asymmetric facial weakness, jaw muscle wasting, and progressive bulbar dysfunction. Patients frequently develop significant dysphagia, dysarthria, and respiratory muscle compromise. Unfortunately, standard diagnostic evaluations often prove inconclusive because routine brain and spinal magnetic resonance scans yield normal structural findings. Electrophysiological testing, such as an absent blink reflex and widespread neurogenic denervation on needle electromyography, remains the conventional diagnostic cornerstone. Nevertheless, the lack of objective structural imaging biomarkers has consistently delayed accurate diagnosis. Physicians frequently misdiagnose affected patients with atypical amyotrophic lateral sclerosis, trigeminal sensory neuropathy, or autoimmune neuropathies. Therefore, identifying definitive imaging abnormalities in the brain represents a critical milestone for clinical practice and disease monitoring.

Advanced Volumetry and FOSMN Neuroimaging Insights

To overcome past neuroimaging limitations, investigators utilized unbiased atlas-based volumetry on volume-rendered high-resolution T1-weighted images in patients diagnosed with FOSMN. By comparing volumetric metrics against healthy matched cohorts, researchers systematically uncovered structural alterations across cerebral and infratentorial regions. Importantly, volumetric data demonstrated marked global brain volume reduction, confirming that the disease reflects a widespread neurodegenerative process rather than a strictly focal peripheral entity. In addition to diffuse cerebral volume loss, the analysis highlighted pronounced regional atrophy localized to the brainstem. Specifically, the medulla oblongata exhibited the most prominent tissue shrinkage among all evaluated infratentorial structures. Because the medulla harbors vital sensory and motor cranial nerve nuclei, this localized atrophy aligns precisely with the patient's severe bulbar symptoms and lower cranial nerve deficits. Moreover, the presence of medullary volume loss provides objective radiological evidence explaining the rapid progression toward speech and swallowing impairments. Thus, advanced volumetric mapping bridges the long-standing diagnostic gap between clinical manifestations and visible structural brainstem neurodegeneration.

Diffusion Tensor Imaging Demonstrates White Matter Tract Disruption

Beyond regional gray matter atrophy, advanced neuroimaging protocols investigated white matter microstructural integrity through diffusion tensor imaging and whole brain-based spatial statistics. Diffusion metrics revealed substantial fractional anisotropy reductions and elevated radial diffusivity within critical projection and association fibers. Notably, investigators identified significant microstructural degradation within the right frontal lobe parenchyma. Furthermore, bilateral tract alterations emerged along both the superior longitudinal fasciculus and the inferior longitudinal fasciculus. These polymodal frontotemporoparietal interconnections play foundational roles in integrating complex sensory feedback and executing coordinated motor commands. When disease processes compromise these large associative pathways, cognitive processing and higher-order sensorimotor integration experience progressive deterioration. Previously, clinicians viewed this disorder primarily as a lower motor neuron and primary sensory neuronopathy. However, these diffusion tensor metrics unequivocally illustrate that central tract pathology accompanies peripheral and brainstem degeneration. Consequently, clinicians must appreciate that white matter degeneration forms an essential component of the full neuropathological spectrum of the disease.

Pathophysiological Links to the Motor Neuron Disease Spectrum

The discovery of both medullary atrophy and polymodal white matter tract involvement provides strong support for a broader neurodegenerative etiology. For years, clinicians debated whether this unusual disorder stemmed from chronic immune-mediated inflammation or primary neurodegeneration. Although some patients received empirical immunotherapies like intravenous immunoglobulin or corticosteroids, most experienced relentless neurological progression without therapeutic benefit. Emerging neuropathological examinations increasingly link the condition to TAR DNA-binding protein 43 (TDP-43) proteinopathy. Pathologists frequently detect these pathological protein aggregates in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. In addition, recent clinical series describe executive cognitive decline and behavioral changes in subsets of affected individuals. The white matter changes discovered along the longitudinal fasciculi and frontal cortex closely mirror the connectivity deficits observed in the frontotemporal spectrum. Therefore, modern neuroimaging data reinforce the concept that this condition belongs within the expanding clinicopathological continuum of motor neuron diseases and frontotemporal spectrum disorders.

Clinical Implications for Neurologists and Radiologists

The identification of distinct brainstem and supratentorial imaging signatures carries substantial implications for modern clinical practice. Neurologists evaluating adult patients with progressive facial sensory loss and bulbar palsy should actively look beyond routine visual inspection of brain MRI scans. Instead, clinicians should collaborate with expert neuroradiologists to incorporate automated volumetric measurements and diffusion tensor sequences. Such advanced quantitative protocols help confirm brainstem medullary atrophy while identifying subclinical disruption of long-range associative tracts. Moreover, early objective identification prevents prolonged diagnostic odyssey and reduces unnecessary immunosuppressive trials that carry serious adverse effects. In medical centers across India and globally, early diagnosis facilitates timely multidisciplinary management. Clinicians can introduce early swallowing assessments, nutritional support via gastrostomy, and timely non-invasive respiratory interventions before life-threatening crises develop. Furthermore, quantitative imaging signatures serve as potential objective biomarkers for future clinical trials evaluating neuroprotective therapies. As scientific consortia collect larger neuroimaging datasets, standardized radiological markers will refine patient stratification and therapeutic monitoring.

Future Perspectives and Research Directions

Although advanced magnetic resonance techniques have revealed pivotal neuroanatomical insights, significant research questions remain unanswered. Current investigations evaluate relatively small patient cohorts due to the extraordinary rarity of the disease worldwide. Consequently, multinational collaborative registries must establish larger multicenter imaging databases to correlate distinct radiological patterns with specific clinical phenotypes. Researchers also need longitudinal neuroimaging studies to map the exact temporal sequence of medullary atrophy and white matter tract deterioration. In addition, scientists should combine advanced imaging biomarkers with fluid biomarkers, such as cerebrospinal fluid and serum neurofilament light chain levels. This multimodal diagnostic approach will enable clinicians to gauge disease activity and measure axonal injury in real time. Ultimately, integrating structural volumetry, tractography, genetics, and molecular biomarkers will deepen our pathophysiological understanding of this condition. Clinicians will then achieve earlier detection, accurate prognostic counseling, and targeted therapeutic interventions for affected individuals.

What is facial onset sensory and motor neuronopathy (FOSMN)?

Facial onset sensory and motor neuronopathy is an exceptionally rare neurodegenerative condition. It typically begins with progressive numbness in the trigeminal nerve distribution. Over months and years, symptoms spread caudally to involve bulbar muscles, neck, and upper extremities, causing marked muscle atrophy, fasciculations, and severe swallowing and respiratory difficulties.

How does advanced neuroimaging assist in diagnosing FOSMN?

Routine brain imaging typically appears normal in affected patients. However, advanced MRI utilizing automated volumetry detects significant global cerebral atrophy and regional brainstem shrinkage, particularly within the medulla oblongata. Furthermore, diffusion tensor imaging reveals microstructural degeneration across polymodal frontotemporoparietal white matter tracts, offering objective biomarkers that confirm central neurodegeneration.

Is FOSMN considered an autoimmune disease or a neurodegenerative disorder?

Although historical theories suggested an autoimmune pathogenesis, the vast majority of patients fail to respond sustainedly to immunosuppressive therapies. Recent postmortem autopsies demonstrate abnormal TDP-43 protein aggregates, while advanced neuroimaging demonstrates cerebral atrophy and tract disruption. Consequently, current scientific consensus classifies the syndrome within the amyotrophic lateral sclerosis and frontotemporal neurodegenerative continuum.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Rosenbohm A et al. Neuroimaging signatures of facial onset sensory and motor neuronopathy (FOSMN). J Neurol. 2026 Oct 05. doi: 10.1007/s00415-026-14174-5. PMID: 42831972.

de Boer EMJ, Barritt AW, Elamin M, et al. Facial Onset Sensory and Motor Neuronopathy: New Cases, Cognitive Changes, and Pathophysiology. Neurol Clin Pract. 2021;11(2):e147-e157.

Vucic S, Kiernan MC, Cornblath DR. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006;129(Pt 12):3384-3395.